TScan Therapeutics, Inc. (TCRX)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Collaboration and license revenue | 3,076 | 2,171 | 1,049 | |
| Research and development | 32,634 | 29,788 | 26,262 | |
| General and administrative | 9,095 | 8,633 | 7,409 | |
| Total operating expenses | 41,729 | 38,421 | 33,671 | |
| Loss from operations | -38,653 | -36,250 | -32,622 | |
| Interest expense | 689 | 679 | 958 | |
| Interest and other income, net | 2,390 | 2,802 | 3,693 | |
| Total other income | 1,701 | 2,123 | 2,735 | |
| Net loss | -36,952 | -34,127 | -29,887 | |
| Net loss per share, basic | -0.28 | -0.26 | -0.25 | |
| Net loss per share, diluted | -0.28 | -0.26 | -0.25 | |
| Weighted-average common shares outstanding, basic | 129,730,451 | 129,678,572 | 118,700,362 | |
| Weighted-average common shares outstanding, diluted | 129,730,451 | 129,678,572 | 118,700,362 | |